New publication highlights basic science supporting simufilam

Austin, texas, june 12, 2023 (globe newswire) -- cassava sciences, inc. (nasdaq: sava), a clinical-stage biotechnology company focused on alzheimer's disease, today announced a new science publication in drug development research, a peer-reviewed journal. this article reviews certain receptor-protein interactions, including an overview of basic science supporting simufilam. simufilam is cassava sciences' oral investigational drug candidate that is currently in phase 3 clinical trials in patients with mild-to-moderate alzheimer's disease dementia.
SAVA Ratings Summary
SAVA Quant Ranking